Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$1.16
-3.3%
$1.22
$0.84
$2.03
$44.23M0.99118,426 shs13,256 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$20.86
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
MUM
70152 (MUM.V)
C$0.18
-2.8%
C$0.17
C$0.10
C$0.52
C$7.36MN/A48,354 shs24,600 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-2.52%+1.75%-2.52%+6.42%-28.40%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
MUM
70152 (MUM.V)
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.6529 of 5 stars
3.50.00.00.03.23.31.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
MUM
70152 (MUM.V)
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.00
Buy$7.00503.45% Upside
CZX
Canada Zinc Metals
N/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/A
MUM
70152 (MUM.V)
N/AN/AN/AN/A

Current Analyst Ratings

Latest MUM, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.88M5.61N/AN/A$2.97 per share0.39
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
MUM
70152 (MUM.V)
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$69.20M-$1.83N/AN/AN/A-878.58%-51.18%-37.81%5/9/2024 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/A5/1/2024 (Confirmed)
MUM
70152 (MUM.V)
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MUM, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.29N/A-C$0.29N/AN/AN/A
3/21/2024Q4 2023
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$0.47-$0.47N/A-$0.47$1.97 million$2.09 million
2/6/2024Q4 2023
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.31C$0.81+C$0.50C$0.81N/AC$171.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
MUM
70152 (MUM.V)
N/AN/AN/AN/AN/A

Latest MUM, BOLT, CZX, and FCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.074.14%4/29/20244/30/20245/15/2024
3/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.073/27/20243/28/20244/15/2024
2/6/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.072/28/20242/29/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.15
5.17
5.17
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A
MUM
70152 (MUM.V)
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
CZX
Canada Zinc Metals
N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/A
MUM
70152 (MUM.V)
N/A

Insider Ownership

CompanyInsider Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
28.40%
CZX
Canada Zinc Metals
N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/A
MUM
70152 (MUM.V)
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
10038.13 million27.30 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable
MUM
70152 (MUM.V)
147,00042.03 millionN/ANot Optionable

MUM, BOLT, CZX, and FCR Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bolt Biotherapeutics logo

Bolt Biotherapeutics

NASDAQ:BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals

CVE:CZX
Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.
First Capital Realty logo

First Capital Realty

TSE:FCR

70152 (MUM.V)

CVE:MUM
Mustang Minerals Corp. explores and develops base and precious metal mineral properties in Canada. It explores for nickel, copper, and platinum group metals. The company primarily focuses on the development of the Mayville Makwa project located in southeastern Manitoba. It also has interests in the Tanco property located in southeast Manitoba; and the East Bull Lake, the River Valley, and the Bannockburn nickel projects located in Ontario. The company was incorporated in 1997 and is headquartered in Toronto, Canada.